Cryospray Therapy Versus Standard of Care for Benign Airway Stenosis (CryoStasis) (NCT04996173)
Cryospray Therapy for Benign Airway Stenosis: a Randomized Pilot Study
🩺 Plain-English Summary (8th-Grade Level)
Benign central airway stenosis (BCAS) is an important cause of both pulmonary morbidity and mortality. Notable causes include post-intubation stenosis, collagen vascular diseases, airway trauma, infectious and idiopathic subglottic stenosis (iSGS). Surgery is the preferred definite option; however, the first therapeutic attempt is usually endoscopic to temporarily restore airway patency and symptomatic improvement. Several endoscopic modalities exist for treatment. Most commonly, thermal or laser therapy to make radial incisions into the stenotic lesion, followed by balloon dilation to increase the area of patency. Clinicians may also inject steroids or antineoplastic agents such as mitomycin C. All of these methods have benefits and associated risks. Symptomatic stenosis frequently reoccurs with these methods. For example, the investigators have been doing 3-4 ballon dilations procedures a week at our institution. Spray cryotherapy (SCT) is a novel FDA-cleared technique that allows for liquid nitrogen to be delivered through the working channel of a bronchoscope. Few retrospective studies exist without more robust clinical trial data to reduce the risk of bias and support its widespread use. The investigators postulate that SCT and standard of care techniques will improve airway patency volume at six months than the standard of care techniques alone. Some of the proposed advantages include improved wound healing which may translate to less scar tissue and thus improvements in airway patency for a longer duration of time.
Who can join: Review the eligibility criteria below.
Location: University of Mississippi Medical Center — Jackson, Mississippi
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of Mississippi Medical Center — Jackson, Mississippi
- Vanderbilt University Medical Center — Nashville, Tennessee
- Virginia Commonwealth University — Richmond, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Disease
- ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent — Los Angeles, California
- DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers — Birmingham, Alabama
- DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer — Los Angeles, California
- Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections — Portland, Oregon
- Natural History Study of Biomarkers in Pulmonary Arterial Hypertension — Bethesda, Maryland
Explore by condition: All Pulmonary Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.